315 related articles for article (PubMed ID: 23348146)
1. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.
Tse HN; Raiteri L; Wong KY; Yee KS; Ng LY; Wai KY; Loo CK; Chan MH
Chest; 2013 Jul; 144(1):106-118. PubMed ID: 23348146
[TBL] [Abstract][Full Text] [Related]
2. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
[TBL] [Abstract][Full Text] [Related]
3. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study.
Stav D; Raz M
Chest; 2009 Aug; 136(2):381-386. PubMed ID: 19447919
[TBL] [Abstract][Full Text] [Related]
4. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.
Wang C; Sun T; Huang Y; Humphries M; Bai L; Li L; Wang Q; Kho P; Firth R; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2015; 10():57-68. PubMed ID: 25609940
[TBL] [Abstract][Full Text] [Related]
6. Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes.
Zhang JQ; Zhang JQ; Liu H; Zhao ZH; Fang LZ; Liu L; Fu WP; Shu JK; Feng JG; Dai LM
Int J Chron Obstruct Pulmon Dis; 2015; 10():917-23. PubMed ID: 25999707
[TBL] [Abstract][Full Text] [Related]
7. High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I-II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China.
Tian H; Zhou Y; Tang L; Wu F; Deng Z; Lin B; Huang P; Wei S; Zhao D; Zheng J; Zhong N; Ran P
Trials; 2020 Sep; 21(1):780. PubMed ID: 32917271
[TBL] [Abstract][Full Text] [Related]
8. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
Tse HN; Tseng CZ
Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
[TBL] [Abstract][Full Text] [Related]
9. Effect of oral N-acetylcysteine on COPD patients with microsatellite polymorphism in the heme oxygenase-1 gene promoter.
Zhang JQ; Zhang JQ; Fang LZ; Liu L; Fu WP; Dai LM
Drug Des Devel Ther; 2015; 9():6379-87. PubMed ID: 26674585
[TBL] [Abstract][Full Text] [Related]
10. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
[TBL] [Abstract][Full Text] [Related]
11. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
12. Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance.
Ambrosino N; Foglio K; Balzano G; Paggiaro PL; Lessi P; Kesten S;
Int J Chron Obstruct Pulmon Dis; 2008; 3(4):771-80. PubMed ID: 19281092
[TBL] [Abstract][Full Text] [Related]
13. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
[TBL] [Abstract][Full Text] [Related]
14. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
Decramer M; Rutten-van Mölken M; Dekhuijzen PN; Troosters T; van Herwaarden C; Pellegrino R; van Schayck CP; Olivieri D; Del Donno M; De Backer W; Lankhorst I; Ardia A
Lancet; 2005 Apr 30-May 6; 365(9470):1552-60. PubMed ID: 15866309
[TBL] [Abstract][Full Text] [Related]
15. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
Johnson K; McEvoy CE; Naqvi S; Wendt C; Reilkoff RA; Kunisaki KM; Wetherbee EE; Nelson D; Tirouvanziam R; Niewoehner DE
Int J Chron Obstruct Pulmon Dis; 2016; 11():799-807. PubMed ID: 27143871
[TBL] [Abstract][Full Text] [Related]
16. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients.
De Backer J; Vos W; Van Holsbeke C; Vinchurkar S; Claes R; Parizel PM; De Backer W
Int J Chron Obstruct Pulmon Dis; 2013; 8():569-79. PubMed ID: 24293993
[TBL] [Abstract][Full Text] [Related]
17. Factorial analysis of N-acetylcysteine and propolis treatment effects on symptoms, life quality and exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD): a randomized, double-blind, placebo-controlled trial.
Kolarov V; Kotur Stevuljević J; Ilić M; Bogdan M; Tušek B; Agic A; Dugajlić M; Tot Vereš K; Kutlešić Stević S; Zvezdin B
Eur Rev Med Pharmacol Sci; 2022 May; 26(9):3192-3199. PubMed ID: 35587070
[TBL] [Abstract][Full Text] [Related]
18. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
[TBL] [Abstract][Full Text] [Related]
19. N-acetylcysteine in patients with COPD exacerbations associated with increased sputum.
Ayfer Aytemur Z; Baysak A; Ozdemir O; Köse T; Sayiner A
Wien Klin Wochenschr; 2015 Apr; 127(7-8):256-61. PubMed ID: 25595117
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.
Tashkin DP; Doherty DE; Kerwin E; Matiz-Bueno CE; Knorr B; Shekar T; Gates D; Staudinger H
Int J Chron Obstruct Pulmon Dis; 2012; 7():73-86. PubMed ID: 22334770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]